Session after session, youll see how your body is reacting to the treatment
They can help determine if this medication is right for you, considering your personal health history and risk factors
Patients considering treatment should seek professional medical guidance before making any changes to medication or dosage
An increased intestinal absorption of bile acids stimulates the secretion of FGF19 from intestinal enterocytes (26), and increasing circulating levels of both bile acids and FGF19 inhibit hepatic bile acid synthesis, as mentioned above
NICE technology appraisal TA875 (semaglutide 2.4 mg, Wegovy) recommends semaglutide as an option for managing overweight and obesity in adults when all of the following criteria are met: [2] [3] BMI of at least 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, obstructive sleep apnoea, or cardiovascular disease), or a BMI of 3034.9 kg/m in specific circumstances defined within the appraisal (for example, recent-onset type 2 diabetes) Treatment is delivered as part of a specialist multidisciplinary weight management service (Tier 3 or equivalent) Use is recommended for a maximum of two years under current NHS commissioning arrangements NICE technology appraisal TA1026 addresses tirzepatide (Mounjaro) for weight management, recommending it for adults with a BMI of 35 kg/m or above alongside at least one weight-related comorbidity, again within a specialist service context
